Docetaxel in stage II, III or IV head and neck cancer - horizon scanning review
NHSC
Record ID 32005000240
English
Authors' objectives:
This study aims to assess the effectiveness of docetaxel in stage II, III or IV head and neck cancer.
Authors' recommendations:
Docetaxel (Taxotere) is an intravenous anti-neoplastic agent that reduces cancer cell division. It is in phase III trials as neoadjuvant and induction chemotherapy for patients with locally advanced head and neck cancer (stage II) and metastatic disease (stage III/IV). In one phase III trial published in abstract, after a median follow up of 32 months, docetaxel added to a neoadjuvant therapy regimen with cisplatin and 5-flurouracil, significantly increased progression free survival from 8.4 months to 12.7 months and overall survival from 14.5 months to 18.6 months.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Head and Neck Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.